In addition, several recently developed EP300/CREBBP bromodomain inhibitors have been reported to mediate antiproliferative responses in hematologic cancer cell lines, such as acute myeloid leukemia (AML) [12, 14] and multiple myeloma [18] cell lines and AR-positive prostate cancer cell lines [16]. Here, CREBBP is linked to hematopoietic and lymphoid cell neoplasm.